Arvinas (ARVN)

• Market cap: $474M
• 1 day: 3.67%
• 5 days: -4.42%
• 1 month: -15.16%
• 3 months: -65.20%
• 6 months: -72.01%
• Year to date: -65.64%
• 1 year: -79.79%
• 5 years: -86.26%
• 10 years: -59.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 430

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

315% more call options, than puts

Call options by funds: $30.8M | Put options by funds: $7.41M

57% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 51

40% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 7 (+2) [Q4]

7.91% more ownership

Funds ownership: 103.54% [Q3] → 111.44% (+7.91%) [Q4]

4% less funds holding

Funds holding: 205 [Q3] → 196 (-9) [Q4]

16% less capital invested

Capital invested by funds: $1.75B [Q3] → $1.47B (-$280M) [Q4]

18% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 34

Research analyst outlook

16 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 23% upside
• Avg. target: $15.66 141% upside
• High target: $28 331% upside

16 analyst ratings

• positive: 10 63%
• neutral: 6 38%
• negative: 0 0%

UBS Eliana Merle 20% 1-year accuracy 4 / 20 met price target	224% upside $21	Buy Maintained	15 May 2025
Morgan Stanley Terence Flynn 41% 1-year accuracy 9 / 22 met price target	69% upside $11	Equal-Weight Maintained	9 May 2025
Citigroup Yigal Nochomovitz 11% 1-year accuracy 4 / 36 met price target	46% upside $9.50	Neutral Maintained	5 May 2025
Truist Securities Srikripa Devarakonda 19% 1-year accuracy 6 / 32 met price target	69% upside $11	Hold Downgraded	5 May 2025
BMO Capital Evan David Seigerman 12% 1-year accuracy 2 / 17 met price target	54% upside $10	Outperform Maintained	5 May 2025